Alcediag

Executive Summary

Alcediag is a French precision psychiatry company based in Montpellier, founded in 2003. It leverages proprietary RNA editing epigenetics and artificial intelligence to develop blood tests for mental health disorders, aiming to provide objective diagnostic and monitoring tools. The company's technology addresses a critical gap in psychiatry, where diagnosis currently relies on subjective assessments. By identifying biomarkers through RNA editing patterns, Alcediag's platform could enable earlier and more accurate detection of conditions such as depression, bipolar disorder, and schizophrenia. As a privately held firm, financial details remain undisclosed, but its focus on a high-unmet-need area positions it for potential growth. The company operates in a competitive diagnostics landscape but differentiates through its novel epigenetic approach and AI integration. Alcediag's success hinges on clinical validation and regulatory approvals, particularly in Europe and the US. While specific pipeline milestones are not public, the growing emphasis on mental health and personalized medicine supports its market opportunity. If commercialization succeeds, Alcediag could become a leader in objective psychiatric diagnostics, though execution risks remain without disclosed revenue or partnerships. Overall, the company represents an innovative but unproven player in precision psychiatry.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation data for lead diagnostic test60% success
• Q4 2026CE marking under IVDR for flagship blood test50% success
• Q2 2026Strategic partnership with pharmaceutical or hospital group40% success